Michael Galgano

Michael Galgano is a patent litigator at Finnegan, Henderson, Farabow, Garrett & Dunner, where his practice focuses on highly technical intellectual property disputes, particularly within the life sciences sector. His work frequently involves biotechnology and pharmaceutical technologies, including gene therapies and recombinant adeno-associated virus (AAV) vectors.

In his tracked appearances, Galgano has exclusively represented defendants, indicating a focus on defending operating companies against infringement allegations. His significant experience includes successfully defending Novartis Gene Therapies, Inc., and related Novartis entities, in multiple patent infringement actions and inter partes review (IPR) proceedings brought by Genzyme Corporation and Aventis Inc..

A notable aspect of his practice is his involvement in the high-stakes litigation, Genzyme Corporation v. Novartis Gene Therapies, Inc., which concerned six patents related to recombinant AAV vector technology underpinning Novartis's gene therapy drug, Zolgensma. The case, along with a related matter concerning analytical ultracentrifugation (AUC) methods, concluded with dismissals with prejudice, with each party bearing its own costs. Finnegan's representation resulted in a favorable outcome for Novartis, with the case settling after four patents were invalidated during claim construction, five patents found not literally infringed, and the institution of multiple IPRs.

Galgano also demonstrates experience with Patent Trial and Appeal Board (PTAB) proceedings, having been involved in the IPRs related to the Genzyme v. Novartis litigation. Furthermore, he has contributed to Finnegan's AIA Blog as an author and editor on IPR and CBM statistics, highlighting his expertise in these post-grant review processes.